Leerink Partners analyst David Risinger reiterated an Outperform rating and {REMOVEPT} price target on Sanofi (NASDAQ: SNY).The analyst comments "SAN ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE